Related Experiment Video
Updated: Aug 15, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 18, 2011
Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering
Patrizia Romualdi1, Sanzio Candeletti
1Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, Bologna, Italy - patrizia.romualdi@unibo.it.
Abstract:
The management of cancer pain presents manifold challenges: even though background pain is adequately controlled, patients frequently experience episodes of acute pain exacerbation known as breakthrough cancer pain (BTcP). The characteristics of BTcP are a rapid onset, a short duration, and a severe intensity. An innovative sublingual fentanyl citrate formulation (Vellofent®) has been developed to target BTcP. The new formulation allows to increase the solubility of fentanyl and to provide optimal oromucosal conditions for rapid drug absorption, thus featuring a shorter time to onset of pain relief (from 6 minutes post-administration).
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Parenteral Anesthetics: Overview
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drug Delivery: Enteral Route
Drugs in...
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral Drug Delivery Systems: Continuous-Release Systems

